- Elicio Therapeutics announced that **99% of evaluable patients (89 of 90)** in its ongoing Phase 2 AMPLIFY-7P trial for ELI-002 7P generated **robust mKRAS-specific T cell responses**.  **[1601485_0001193125-25-205522_d38971dex991.htm:0]** **[1601485_0001193125-25-205522_d38971d8k.htm:2]** 
- The observed T cell responses showed an **average increase of 145.3x over baseline** (median **44.3x**), consistent with prior Phase 1 trials where such responses correlated with clinical activity.  **[1601485_0001193125-25-205522_d38971dex991.htm:0]** **[1601485_0001193125-25-205522_d38971d8k.htm:2]** 
- An Independent Data Monitoring Committee recommended that the trial continue to the final analysis without modifications, which Elicio believes indicates preliminary signals of efficacy.  **[1601485_0001193125-25-205522_d38971dex991.htm:1]** **[1601485_0001193125-25-205522_d38971dex991.htm:3]** 
- The final disease-free survival analysis for the AMPLIFY-7P trial is anticipated in the **fourth quarter of 2025**.  **[1601485_0001193125-25-205522_d38971dex991.htm:0]** **[1601485_0001193125-25-205522_d38971dex992.htm:1]** **[1601485_0001193125-25-205522_d38971dex991.htm:3]**

Elicio Therapeutics (ELTX)